Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

astrazeneca ab - metforminas hidrochloridas, saxagliptin, dapagliflozin - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - qtrilmet yra nurodyta suaugusiems nuo 18 metų ir vyresni, su 2 tipo cukrinis diabetas:gerinti glycaemic kontrolės, kai metforminas su arba be sulfonilkarbamido dariniai (Šu) ir arba saxagliptin ar dapagliflozin neužtikrina adekvačios glycaemic kontrolės. kai jau gydomi metforminas ir saxagliptin ir dapagliflozin.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

astrazeneca ab  - metforminas hidrochloridas, saxagliptin hidrochloridas - cukrinis diabetas, 2 tipas - drugs used in diabetes, combinations of oral blood glucose lowering drugs - komboglyze skiriamas kartu su dieta ir pagerinti glikemijos kontrolę sergantiems suaugusiesiems nuo 18 metų amžiaus ir vyresni 2 tipo cukriniu diabetu sergantiems glikemija kontroliuojama jų toleruojamą vien metforminu arba kurių jau yra su saksagliptinas ir metforminu atskiromis tabletėmis. komboglyze taip pat nurodė, kartu su insulino (i. trigubas derinys terapija), kaip papildoma priemonė kartu su dieta ir mankšta pagerinti glycaemic kontrolės suaugusių pacientų, vyresnių kaip 18 metų ir vyresnio amžiaus, su 2 tipo cukriniu diabetu, kai insulino ir metforminas vien nesuteikia pakankamos kontrolės glycaemic.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

astra zeneca ab - saxagliptin, dapagliflozin propandiolis monohidratas - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - narkotikai, vartojami diabetu - qtern, fiksuotų dozių derinys saxagliptin ir dapagliflozin, yra nurodyta suaugusiems žmonėms nuo 18 metų ir vyresni, su 2 tipo cukrinis diabetas:gerinti glycaemic kontrolės, kai metforminas ir (arba) sulfonilkarbamido dariniai (Šu) ir viena monocomponents, qtern nesuteikia pakankamos glycaemic kontrolės,kai jau gydomi nemokamai derinys dapagliflozin ir saxagliptin. (Žr. skirsnius 4. 2, 4. 4, 4. 5 ir 5. 1 duomenys apie derinius studijavo.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , trigubas derinys terapija), kaip papildoma priemonė kartu su dieta ir fiziniais pratimais pacientams, nepakankamai kontroliuojama, jų maksimali toleruojama dozė metforminas ir sulfonilkarbamido dariniai. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , trigubas derinys terapija), kaip papildoma priemonė kartu su dieta ir fiziniais pratimais pacientams, nepakankamai kontroliuojama, jų maksimali toleruojama dozė metforminas ir sulfonilkarbamido dariniai. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , trigubas derinys terapija), kaip papildoma priemonė kartu su dieta ir fiziniais pratimais pacientams, nepakankamai kontroliuojama, jų maksimali toleruojama dozė metforminas ir sulfonilkarbamido dariniai. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

as grindeks - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/850 mg - metformin and sitagliptin

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

as grindeks - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/1000 mg - metformin and sitagliptin

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva gmbh - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/850 mg - metformin and sitagliptin